Acusphere

Director Development

Robert Z......

Dr. Robert Z...... has over 20 years of drug discovery and development experience and currently serves as Vice President and Senior Fellow, Drug Development of Concert Pharmaceuticals, Inc.

Prior to joining Concert in July 2006 he held key positions at Scion Pharmaceuticals, Acusphere, Vertex Pharmaceuticals and Abbott Laboratories.

Before Concert, Dr. Z...... founded Bell Rock Associates, a pharmaceutical development consulting firm.

He also served as Vice President of Chemistry at Scion where he was responsible for discovery chemistry, manufacturing, intellectual property and regulatory submissions.

Before Scion, he was Senior Director of Regulatory Affairs and Product Development at Acusphere. In this role he was responsible for regulatory affairs, quality assurance, quality control and preclinical testing.

Dr. Z...... has been granted 24 U.S. patents with numerous pending U.S. applications. Dr.

Sherri C......

Ms. Sherri C...... , a co-founder of Acusphere, has served as the President and Chief Executive Officer and one of the directors since inception in 1993. Prior to joining Acusphere, Ms. was President and Chief Executive Officer of Neomorphics, Inc., a venture capital backed company focused on tissue engineering. Prior to joining Neomorphics, she was a venture capitalist at Aegis Venture Funds, and at Inco Venture Capital Management. She was formerly a member of the board of directors and executive committee of the Massachusetts Biotechnology Council. Ms. is a Trustee of Dartmouth College and a member of the Board of Overseers of The Amos Tuck School at Dartmouth College. Ms. holds a B.A. from Dartmouth College and an M.B.A. from the Amos Tuck School of Business Administration.

Robert S......

Robert S...... is the David H. Koch Institute Professor (there are 14 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). Dr. has written nearly 1,130 articles. He also has approximately 800 issued and pending patents worldwide. Dr. s patents have been licensed or sublicensed to over 220 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history.


He served as a member of the United States Food and Drug Administrations SCIENCE Board, the FDAs highest advisory board, from 1995 - 2002 and as its Chairman from 1999 - 2002.

Dr.

Daniel G......

Daniel E. G...... is the founder and managing director of Danforth Advisors, a consulting firm providing administrative, strategic and operational support to life science companies. He has more than 20 years of experience in the life science industry, with companies ranging from early startups to publicly-traded companies with over $1 billion market capitalizations. Previously, he served as chief operating officer or chief financial officer of four publicly-traded and four privately-held companies, in addition to his consulting clients, and was interim chief executive officer of a medical device company.

In these roles, he held management responsibility for finance, accounting, human resources, investor/public relations, facilities, legal, intellectual property and manufacturing functions. Mr.

Martyn G......

Mr. Martyn G...... formerly served as a director of Cephalon, Inc. and as Chairman of BMP Sunstone Corporation, a pharmaceutical company based in China which had grown to over $100 million in revenue since he joined at the formation stage in 2004 and was then sold to Sanofi-Aventis in February 2011. Mr. G...... also served as Chief Executive Officer and director of Delsys Pharmaceutical Corporation, a formulation and drug delivery system company; as President and Chief Executive Officer and as a director of Zynaxis Inc., a biopharmaceutical company; and as Chairman Europe, SmithKline Beecham Pharmaceutical Company. He joined SmithKline & French in 1973, where he held positions of increasing responsibility in its European organization. Mr. G...... serves as Chairman of Life Mist Technologies, Inc., a fire suppression equipment company, and as a director of Curis, Inc. and Neostem, Inc.